Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study to Assess the Safety and Tolerability of CD70-targeting CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

NCT05468190 is registered in ClinicalTrials.gov with Chongqing Precision Biotech Co., Ltd as lead sponsor.

NCT NCT05468190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05468190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study to Assess the Safety and Tolerability of CD70-targeting CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
Lead sponsor
Chongqing Precision Biotech Co., Ltd
Phase
Phase 1
Overall status
Unknown status
Start date
July 17, 2022
Completion date
July 17, 2025
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, cervix cancer, metastatic tumor, ovarian cancer, renal cell carcinoma